Oncology Research Editorial Office

Oncology Research, Vol.32, No.10, pp. 1689-1690, 2024, DOI:10.32604/or.2024.056905 - 18 September 2024

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.9, pp. 1541-1541, 2024, DOI:10.32604/or.2024.056127 - 23 August 2024

Abstract This article has no abstract. More >

SHAN JIANG^1,2, XIUFENG LIN², YANFEI CHEN³, XINNING LI³, JIALI KANG^1,4,*

BIOCELL, Vol.48, No.8, pp. 1265-1273, 2024, DOI:10.32604/biocell.2024.051478 - 02 August 2024

Abstract Background: Despite improvements in objective response rates to cisplatin-based combination chemotherapy, the majority of advanced ovarian cancer remains suboptimal, resulting in poor survival. it has been found that non-coding RNAs (ncRNAs) not only participate in the transmission of signals between various cells but also participate in tumor immunity and anti-tumor immune responses, thereby regulating tumor occurrence and development. However, the function and detailed mechanism of ultraconserved RNA (ucRNA) in ovarian cancer chemoresistance is still unclear. Methods: Western blotting assay, Quantitative real-time PCR analysis (qPCR), and Kaplan-Meier Plotter analysis were performed to analyze the expression and prognosis… More >

EFFAT ALEMZADEH¹, LEILA ALLAHQOLI², AFROOZ MAZIDIMORADI³, ESMAT ALEMZADEH^1,4, FAHIMEH GHASEMI^4,5, HAMID SALEHINIYA⁶, IBRAHIM ALKATOUT^7,*

Oncology Research, Vol.32, No.5, pp. 831-847, 2024, DOI:10.32604/or.2024.031006 - 23 April 2024

Abstract Ovarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for maintenance therapy. However, resistance to these new drugs has emerged. Therefore, understanding the mechanisms of DR and exploring new approaches to overcome More >

LISHA MA^1,#, WANQI SHAO^1,#, WEILI ZHU^2,*

BIOCELL, Vol.48, No.3, pp. 379-386, 2024, DOI:10.32604/biocell.2024.047812 - 15 March 2024

Abstract The morbidity rate of ovarian cancer, a malignant tumour in gynaecological tumours, is rising, and it is considered to be the most lethal cancer. The majority of patients are typically diagnosed during the advanced stages of the illness due to the elusive characteristics of ovarian cancer and an absence of highly sensitive and specific diagnostic indicators. Surgical excision of the lesions, along with chemotherapy, is the conventional treatment for ovarian cancer; however, resistance to platinum-based chemotherapeutic drugs and molecular targeted therapies frequently arises. Improving the survival rate and prognosis of patients with end-stage or recurring… More >

JIANFA WU^1,2,#, QIANYI LIAO^3,#, LI ZHANG^1,2,#, SUQIN WU^1,2,*, ZHOU LIU^1,2,*

Oncology Research, Vol.32, No.2, pp. 373-391, 2024, DOI:10.32604/or.2023.031404 - 28 December 2023

Abstract The impact of different iron metabolism processes (DIMP) on ovarian cancer remains unclear. In this study, we employed various gene chips and databases to investigate the role of DIMP in the initiation and development of ovarian cancer. cBioPortal was used to determine mutations in DIMP-associated genes in ovarian cancer. Kaplan-Meier plotter was used to examine the influence of DIMP on the prognosis of ovarian cancer. By analyzing 1669 serous ovarian cancer cases, we identified a range of mutations in iron metabolism genes, notably in those coding for the transferrin receptor (19%), melanotransferrin (19%), and ceruloplasmin… More >

TING ZHOU^1,#, PEIYING FU^1,#, DONG CHEN², RONGHUA LIU^1,*

Oncology Research, Vol.31, No.5, pp. 769-785, 2023, DOI:10.32604/or.2023.030166 - 21 July 2023

Abstract Late-stage ovarian cancer (OC) has a poor prognosis and a high metastasis rate, but the underlying molecular mechanism is unclear. RNA binding proteins (RBPs) play important roles in posttranscriptional regulation in the contexts of neoplasia and tumor metastasis. In this study, we explored the molecular functions of a canonical RBP, Transformer 2β homolog (TRA2B), in cancer cells. TRA2B knockdown in HeLa cells and subsequent whole-transcriptome RNA sequencing (RNA-seq) analysis revealed the TRA2B-regulated alternative splicing (AS) profile. We disrupted TRA2B expression in epithelial OC cells and performed a series of experiments to confirm the resulting effects… More >

TIANMING SHI^1,2,#, RONGRONG YAN^1,2,#, MI HAN^1,2,*

Oncology Research, Vol.31, No.4, pp. 591-604, 2023, DOI:10.32604/or.2023.029282 - 25 June 2023

Abstract Ovarian cancer (OV) is highly heterogeneous tumor with a very poor prognosis. Studies increasingly show that T cell exhaustion is prognostically relevant in OV. The aim of this study was to dissect the heterogeneity of T cell subclusters in OV through single cell transcriptomic analysis. The single RNA-sequencing (scRNA-seq) data of five OV patients were analyzed, and six major cell clusters were identified after threshold screening. Further clustering of T cell-associated clusters revealed four subtypes. Pathways related to oxidative phosphorylation, G2M checkpoint, JAK-STAT and MAPK signaling were significantly activated, while the p53 pathway was inhibited… More > Graphic Abstract

YAPING GAN^1,2,#, TING LIU^3,#, WEIFENG FENG^1,#, LIANG WANG⁴, LI LI⁵, YINGXIA NING^1,*

Oncology Research, Vol.31, No.3, pp. 333-343, 2023, DOI:10.32604/or.2023.028694 - 22 May 2023

Abstract Various therapeutic strategies have been developed to overcome ovarian cancer. However, the prognoses resulting from these strategies are still unclear. In the present work, we screened 54 small molecule compounds approved by the FDA to identify novel agents that could inhibit the viability of human epithelial ovarian cancer cells. Among these, we identified disulfiram (DSF), an old alcohol-abuse drug, as a potential inducer of cell death in ovarian cancer. Mechanistically, DSF treatment significantly reduced the expression of the anti-apoptosis marker B-cell lymphoma/leukemia-2 (Bcl-2) and increase the expression of the apoptotic molecules Bcl2 associated X (Bax)… More >

QINGLING TANG¹, WARDA ATIQ², SHAISTA MAHNOOR², MOSTAFA A. ABDEL-MAKSOUD³, MOHAMMED AUFY⁴, HAMID YAZ^3,*, JIANYU ZHU^5,*

Oncology Research, Vol.31, No.2, pp. 141-156, 2023, DOI:10.32604/or.2023.028548 - 10 April 2023

Abstract Though significant improvements have been made in the treatment methods for ovarian cancer (OC), the prognosis for OC patients is still poor. Exploring hub genes associated with the development of OC and utilizing them as appropriate potential biomarkers or therapeutic targets is highly valuable. In this study, the differentially expressed genes (DEGs) were identified from an independent GSE69428 Gene Expression Omnibus (GEO) dataset between OC and control samples. The DEGs were processed to construct the protein-protein interaction (PPI) network using STRING. Later, hub genes were identified through Cytohubba analysis of the Cytoscape. Expression and survival… More >